Table 1.

Clinicopathological Characteristics of Two Population-based Prostate Cancer Patient Cohorts

	Seattle Cohort (N=1,309)		Swedish Cohort (N=2,875)
	N	%	N	%
Age at diagnosis, years
Mean	59.9		65.8
Median	60.0		64.9
Range	35.0 – 74.0		44.6 – 80.4
Follow-up time, years
Mean	8.5		6.0
Median	6.5		6.5
Range	0.8 – 15.9		0.3 – 8.6
Prostate cancer-specific death
No1	1,249	95.4	2,374	82.6
Yes	60	4.6	501	17.4
Age at death, years
Mean	63.9		71.2
Median	65.2		71.2
Range	44.9–78.3		48.5–85.7
Stage
Local	1,023	78.2	1,885	65.6
Regional	254	19.4	651	22.6
Distant	32	2.4	266	9.3
Missing	0	0.0	73	2.5
Gleason score
2 – 4	67	5.1	106	3.7
5 – 6	680	51.9	1,269	44.1
7	432	33.0	782	27.2
8 – 10	126	9.6	467	16.2
Missing	4	0.3	251	8.7
Diagnostic PSA level, ng/mL
< 4	178	13.6	148	5.1
4 – 9.9	722	55.2	993	34.5
10 – 19.9	191	14.6	651	22.6
≥ 20	118	9.0	1,003	34.9
Missing	100	7.6	80	2.8
Primary therapy
Radical prostatectomy	770	58.8	713	24.8
Radiation therapy	359	27.4	682	23.7
Androgen deprivation	61	4.7	927	32.2
None	115	8.8	488	17.0
Other	4	0.3	22	0.8
Missing	0	0.0	43	1.5

¹Includes men who died of other causes and were censored at time of death (Seattle, n=102; Sweden, n=258)